What Vitaros HEXAL Treats: Main Uses

Vitaros HEXAL is a medicine indicated for the management of erectile dysfunction (ED) in men 18 years of age and older. Erectile dysfunction is defined as the persistent inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.

Therapeutic Use and Benefits

The primary therapeutic objective of Vitaros HEXAL is to promote the ability to achieve penile erection. The medicine's active component increases blood flow to the erectile tissues of the penis, which facilitates the creation of penile rigidity necessary for sexual activity. The clinical benefits include a rapid onset of effect, typically within 5 to 30 minutes after application, which supports a successful attempt at sexual intercourse.

This topical formulation serves as a treatment option for individuals who may not be suitable for, or do not respond to, oral therapies for erectile dysfunction. The treatment has been demonstrated to improve erectile function across various patient populations, including those with underlying conditions such as diabetes and cardiovascular disease.

---

Quick Facts: Therapeutic Domain

• Main Indication: Treatment of erectile dysfunction (ED).
• Therapeutic Action: Facilitates the ability to achieve and maintain a penile erection.
• Target Population: Adult men 18 years of age and older.

Eligibility Map: Official Regulatory Information

Vitaros HEXAL is officially indicated for the treatment of men mathbfgeq 18 years of age with erectile dysfunction. The regulatory label defines strict exclusions for use, primarily based on underlying health status and local anatomical condition.

Category	Eligibility Rule/Status
Approved Age Group	Men 18 years of age. Not intended for children or men below 18 years. No dose adjustment is necessary for elderly men (65 years).
Populations Contraindicated	Use is prohibited in patients with conditions that predispose to priapism (e.g., sickle cell disease, leukemia, multiple myeloma). Contraindicated in men with abnormal penile anatomy (e.g., curvature, severe hypospadias) or inflammation (urethritis, balanitis).
Systemic Restrictions	Prohibited for men with underlying disorders such as orthostatic hypotension, recent myocardial infarction, syncope, or unstable cardiovascular or cerebrovascular conditions for whom sexual activity is inadvisable.
Conditional Use	A condom barrier must be used during sexual intercourse with a woman who is pregnant, breastfeeding, or of child-bearing potential.
Organ Function	Pharmacokinetics have not been formally studied in patients with hepatic and/or renal insufficiency; dose may need to be lowered in these populations.

The medicine must not be used in combination with oral Phosphodiesterase-5 (PDE5) inhibitors. The official documents strictly define these populations who are excluded from use (contraindicated) or require specific protective measures (conditional use).

Vitaros HEXAL's official interaction profile is defined primarily by documented pharmacodynamic effects related to its local vasodilatory action. Governmental documents classify several co-administered substances as having a potential for additive risks, resulting in specific constraints. Formal pharmacokinetic interaction studies have not been performed, and metabolic interactions are considered unlikely.

Prohibited Combinations

The use of Vitaros HEXAL in combination with Phosphodiesterase-5 (PDE-5) Inhibitors, including sildenafil, tadalafil, and vardenafil, is strictly prohibited by regulatory documentation. This prohibition is due to the potential for an unstudied, but additive, increase in cardiovascular risk.

Other Documented Pharmacodynamic Interactions

The official label outlines several interaction risks:

• Increased Hypotension Risk: Co-administration with antihypertensive drugs or other vasoactive medications is associated with an increased risk of low blood pressure. This risk is noted to be greater in elderly patients.
• Prolonged Erection Risk: Combining Vitaros with other erection-inducing agents, such as Smooth Muscle Relaxants (e.g., papaverine) or Alpha-blocking Drugs, carries a documented risk of priapism.
• Bleeding Risk: Use with Anticoagulants and Platelet Aggregation Inhibitors is linked to an increased risk of urethral bleeding.
• Reduced Effect: Concurrent use with substances like Sympathomimetics may result in a reduced overall effect of alprostadil.

Targeting Specific Molecular Receptors

The active compound initiates its action by activating Prostaglandin E2 Receptors (specifically EP4/2) located on local smooth muscle cells. This targeted molecular event constitutes the initial event in the subsequent cellular cascade.

---

Triggering the Relaxation Cascade

Activation of these receptors leads to a cascade that rapidly increases intracellular cyclic adenosine monophosphate ( cAMP) levels. This signal functions to lower the concentration of calcium ( Ca^2+) inside the smooth muscle cells.

---

Modulating Local Vascular Tone and Flow

The reduction in intracellular calcium induces relaxation of the cavernosal smooth muscle. This physiological effect widens the local arteries and alters the hydrodynamics of local blood flow, which produces the resulting vascular engorgement.

How to Use Vitaros HEXAL

Vitaros HEXAL is a medicine designated for topical administration to the tip of the penis (meatus) using a pre-filled, single-use AccuDose container. The medicine is used as needed (pro re nata, PRN) to achieve an erection.

---

Official Dosing and Frequency

Instruction Entity	Official Labeled Guideline
Route	Topical, applied to the opening at the tip of the penis (meatus).
Available Strengths	200 mug and 300 mug alprostadil per 100 mg of cream.
Maximum Frequency	No more than 2–3 times per week and only once per 24-hour period.
Age Restriction	Not indicated for men below 18 years of age.

---

Administration Timing and Preparation

The entire dose from the single-use AccuDose container must be applied 5 to 30 minutes before attempting intercourse. Prior to application, it is recommended to urinate. The container's contents should be warmed to room temperature by rolling it between the hands to facilitate application.

Procedural and Handling Constraints

The cream is expelled into the meatus opening without inserting the container tip. Following administration, the penis should be held upright for approximately 30 seconds to promote absorption of the cream into the urethra. Each AccuDose container is for single use only and must be properly discarded after a single administration, even if some cream remains. Only latex-based condoms have been investigated for concurrent use with this product.

Vitaros HEXAL: Overview of Core Clinical Studies

Evidence for Use in Treating Erectile Dysfunction (ED)

The foundational research for topical alprostadil cream evaluated its use in adult men with erectile dysfunction (ED). The primary data came from large, short-term randomized controlled trials (RCTs), typically lasting 12 weeks, which compared the active formulation against a placebo cream. Researchers examined outcomes primarily focused on function, using standardized scores and patient-reported outcomes describing perceived functional limitation and success during sexual activity. The findings describe patterns observed in the studies where data show patterns related to functional measurements recorded in the active formulation group compared to those in the placebo group over the short observation period.

Evidence in Patient Groups with Co-existing Conditions

The research was evaluated in specific patient groups, including men whose ED was associated with underlying conditions such as stable cardiovascular disease, diabetes, or hypertension. The cream was studied for use in men with ED following prostatectomy. Subgroup findings describe patterns observed in the studies that were broadly consistent with the general population. However, the evidence for these specific subgroups is often categorized as moderate due to the relatively smaller number of participants from these groups.

Long-Term Study Duration and Research Gaps

The core function research consisted of the short-term, placebo-controlled trials, supplemented by subsequent open-label extension trials for durations up to six to nine months. These extended studies provide context but not individual predictions regarding sustained use. However, long-term effects are not fully established, as the follow-up durations were limited. Additionally, a significant aspect of the research is that comparative evidence is lacking—no published randomized studies research examined this cream directly against other widely used ED treatments. Evidence quality varies across studies, and regulatory reviews have noted that the absolute amount of change in functional scores may have been modest in the pivotal trials.

Key Studies & References

1. Public Assessment Report Scientific discussion Vitaros 200 micrograms and 300 micrograms, cream (alprostadil) NL/H/3144/001-002

Common questions about Vitaros HEXAL (FAQ)

Q: How long does the effect of Vitaros HEXAL typically last?

A: Official product information describes the typical duration of the effect as approximately 1 to 2 hours after administration. Regulatory documents indicate that the actual time the effect lasts may vary among individuals.

Q: Is it normal to feel a warming sensation after application?

A: Official safety information for Vitaros HEXAL lists a penile burning sensation as a common side effect experienced by some users. A warming sensation may be related to this documented penile burning sensation, which is noted in the official safety information.

Q: What happens if I use Vitaros HEXAL more often than recommended?

A: Regulatory documents state that using the medicine more often than the officially approved frequency may lead to specific risks. Potential effects documented in the overdose section include a drop in blood pressure, fainting (syncope), dizziness, persistent penile pain, and the potential for a prolonged erection (priapism).

Q: Does alcohol affect how Vitaros HEXAL works?

A: According to official resources for Vitaros HEXAL, its function is not known to be affected by food or alcohol consumption. Regulatory documentation notes that its action is local and independent of systemic factors like food or drink.

Q: Does Vitaros HEXAL help with premature ejaculation?

A: The medicine is officially indicated only for the treatment of erectile dysfunction (ED) in men aged 18 years and older. Regulatory documents do not list premature ejaculation as an approved use for this product.

Q: Are there specific food restrictions while using Vitaros HEXAL?

A: Studies and official information indicate that Vitaros HEXAL is not known to be affected by food consumption. Therefore, there are no specific food restrictions mentioned in the regulatory product information.

Q: Does Vitaros HEXAL interact with recreational drugs?

A: Official regulatory documents specifically address potential interactions with prescription and over-the-counter medicines (such as PDE-5 inhibitors or blood pressure medications). However, these documents do not specifically list interactions with recreational drugs.

Q: Does Vitaros HEXAL have a noticeable smell?

A: The official product description defines the medicine as a white to off-white cream but does not contain detailed information regarding its smell or odor.

Q: Is Vitaros HEXAL an FDA-approved drug in the US?

A: The US Food and Drug Administration (FDA) has not approved Vitaros for use in the United States. Regulatory approval has been granted in certain international regions, but this specific product is not available through authorized channels in the US.

Q: Does using Vitaros HEXAL affect semen quality?

A: Studies of the active ingredient, alprostadil, using transurethral delivery found no significant impact on the motility, viability, or membrane integrity of human sperm. The research examined these specific aspects of semen quality.

Q: Are there any studies focusing on Vitaros HEXAL use in patients with nerve damage?

A: Clinical efficacy studies were evaluated in patient groups whose erectile dysfunction was associated with underlying conditions such as diabetes or occurred following a prostatectomy. While these conditions may involve issues relevant to nerve function, 'nerve damage' itself is not listed as a distinct, officially studied patient population.

Q: Why do official documents mention specific underlying conditions for which Vitaros HEXAL is not recommended?

A: Official documents define these exclusions for patient safety based on two main factors. Certain conditions (like sickle cell disease or multiple myeloma) may predispose to priapism (a prolonged erection). Other conditions (like recent heart attack or unstable cardiovascular disease) mean that sexual activity is considered inadvisable for the patient.

How to Store and Dispose of Vitaros HEXAL

Official regulatory guidelines strictly define the storage and disposal requirements for Vitaros HEXAL:

• Mandatory Storage Temperature: This medicine must be stored in a refrigerator, maintained between 2 C and 8 C. Do not freeze the product.

• Short-Term Stability: Unopened sachets may be kept out of the refrigerator below 25 C for a maximum of 3 days. Sachets stored longer than 3 days, or above this temperature, must be discarded.

• Protection Requirements: The product must be stored in its original sachet to ensure protection from light.

• Handling: The AccuDose container is for single use only. Once the sachet is opened, the contents must be used immediately, and any unused portion must be discarded.

• Disposal: After use, the container should be secured by placing it back into the opened foil sachet and folding it. Any unused medicine or waste material must be disposed of in accordance with local requirements.

• Child Safety: Always keep this medicine out of the sight and reach of children.